ISSCR News
Repurposing Drugs to Eliminate Cellular Origins of Brain Tumors
In an effort to rapidly identify new treatments effective against BTSCs, a team of researchers from the University of Ottawa, Canada, tested Edaravone, an FDA-approved drug, for its efficacy against BTSCs, knowing that Edaravone blocks cellular processes which are important for the growth and survival of BTSCs.
New Podcast Episode. PSC Developmental Bias: The Mechanism and the Variation in Human Neural Development
The guests on this episode of The Stem Cell Report studied functional variation in human PSC lines as they progress through neurectoderm versus mesendoderm lineages and fore- versus hind-brain development. They will discuss the origin and consequences of inter-individual variation in the early events orchestrating human neural development, the extent to which such variation might impact on adult health and disease, and how it might be exploited in stem cell therapy.
Member Spotlight: Kirsten Sadler (Edepli), PhD
I love learning, and I am intrinsically curious. By far the most rewarding part of the job is engaging in scientific discussions about data with my colleagues and members of my team.
Registration and Abstract Submission Now Open for the ISSCR 2025 Annual Meeting
Registration and abstract submission are open for the ISSCR 2025 Annual Meeting, where academic and industry innovators in stem cell science and regenerative medicine will gather for The Global Stem Cell Event 11-14 June in Hong Kong for the first time in the ISSCR’s history. The ISSCR extends its thanks to co-sponsors The University of Hong Kong, The Chinese University of Hong Kong, and The Hong Kong University of Science and Technology for their support of the meeting.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .